Vaccinex/ US9186403013 /
2024-08-02 5:24:56 PM | Chg. -0.01 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
4.75USD | -0.11% | 1,290 Turnover: 6,529.14 |
-Bid Size: - | -Ask Size: - | 5.31 | 4.75 |
GlobeNewswire
06-06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
05-16
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
03-27
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Pr...
GlobeNewswire
02-21
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
GlobeNewswire
01-03
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire
2023-12-04
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
2023-11-13
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-31
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combinat...
GlobeNewswire
2023-10-26
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Ne...
GlobeNewswire
2023-09-28
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Va...
GlobeNewswire
2023-09-27
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
GlobeNewswire
2023-09-26
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab ...
GlobeNewswire
2022-02-24
Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
GlobeNewswire
2022-01-26
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B...
GlobeNewswire
2021-11-10
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
GlobeNewswire
2021-11-09
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
GlobeNewswire
2021-11-08
Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
GlobeNewswire
2021-11-04
Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
GlobeNewswire
2021-11-01
Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021